United Asset Strategies Inc. Grows Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

United Asset Strategies Inc. increased its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 5.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 3,951 shares of the pharmaceutical company’s stock after purchasing an additional 196 shares during the period. United Asset Strategies Inc.’s holdings in Vertex Pharmaceuticals were worth $1,591,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Northwest Investment Counselors LLC acquired a new stake in shares of Vertex Pharmaceuticals during the third quarter worth about $25,000. Highline Wealth Partners LLC acquired a new stake in Vertex Pharmaceuticals during the 3rd quarter worth approximately $27,000. Dunhill Financial LLC lifted its holdings in Vertex Pharmaceuticals by 70.6% during the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock worth $27,000 after buying an additional 24 shares in the last quarter. Legacy Investment Solutions LLC acquired a new position in shares of Vertex Pharmaceuticals in the third quarter worth $33,000. Finally, Truvestments Capital LLC purchased a new stake in shares of Vertex Pharmaceuticals during the third quarter worth $35,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Vertex Pharmaceuticals Trading Down 0.0 %

Shares of VRTX stock opened at $439.62 on Monday. Vertex Pharmaceuticals Incorporated has a 1-year low of $377.85 and a 1-year high of $519.88. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.47 and a quick ratio of 2.20. The business’s fifty day moving average price is $435.36 and its 200 day moving average price is $464.32. The firm has a market capitalization of $113.22 billion, a PE ratio of -220.91, a P/E/G ratio of 2.20 and a beta of 0.40.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.61 by $0.77. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The business had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.69 billion. During the same quarter last year, the firm posted $3.67 EPS. The business’s revenue was up 11.6% compared to the same quarter last year. As a group, sell-side analysts forecast that Vertex Pharmaceuticals Incorporated will post -1.9 EPS for the current fiscal year.

Wall Street Analyst Weigh In

VRTX has been the subject of several recent research reports. William Blair reiterated an “outperform” rating on shares of Vertex Pharmaceuticals in a research note on Monday, January 13th. Scotiabank boosted their price target on shares of Vertex Pharmaceuticals from $426.00 to $430.00 and gave the stock a “sector perform” rating in a report on Monday, December 23rd. JPMorgan Chase & Co. reduced their price objective on shares of Vertex Pharmaceuticals from $503.00 to $500.00 and set an “overweight” rating on the stock in a report on Monday, December 23rd. Jefferies Financial Group raised Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and increased their target price for the company from $500.00 to $550.00 in a report on Monday, December 9th. Finally, BMO Capital Markets lowered their price objective on Vertex Pharmaceuticals from $566.00 to $520.00 and set an “outperform” rating for the company in a research report on Friday, December 20th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Vertex Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $494.84.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.